Andarix Pharmaceuticals Selected to Present at the 14th Annual Targeted Therapies for Lung Cancer Meeting

Company Will Present its Targeted and Personalized Medicine Approach to Lung Cancer

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Somerville, MA (PRWEB) February 18, 2014

Andarix Pharmaceuticals, a clinical stage company, announces that it has been selected to present its targeted lung cancer therapy at the 14th Annual Targeted Therapies of the Treatment of Lung Cancer Meeting, also known as the Santa Monica Lung Cancer Meeting. This annual invitation-only meeting gathers the top scientists and clinicians to discuss the latest advances in the treatment of lung cancer with targeted therapies.

“We are pleased to have been selected to present our targeted lung cancer therapy, P2045, to a prestigious group of lung cancer specialists. P2045 is preparing to enter additional clinical studies, and to date has shown promising results,” says Chris Adams, Chief Executive Officer.

About P2045
P2045 is a novel, best-in-class therapy for lung and other cancers based on a radio-labeled somatostatin peptide analogue. Early clinical studies of P2045 demonstrated that it is well tolerated and may produce prolonged stable disease and improved overall survival in advanced lung cancer patients whose disease has continued to progress after failing other therapies. P2045 targeted radiotherapy represents a new treatment paradigm which is expected to yield significant clinical benefit for both small cell lung cancer (SCLC), and non-small cell (NSCLC) patients, and which will provide another treatment option for patients who are not eligible for, or who have not responded to current therapies.

About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer, developing both the imaging agents that can identify appropriate patients, as well as the targeted therapies for these patients. The company’s products have progressed through early clinical development. The Andarix technology is based on a proprietary somatostatin peptide conjugate applicable to lung, neuroendocrine, and other cancers Extensive research has demonstrated that somatostatin receptors are highly up-regulated on several solid tumors, particularly lung cancers. Lung cancer is the leading cause of cancer mortality in the United States, with over 170,000 new diagnoses of non-small cell lung cancer (NSCLC) and over 150,000 deaths attributable to this disease annually. To learn more about Andarix, please visit http://www.andarix.com.


Contact